◆ FUNDING DATA
- Round
- Series D
- Amount
- $80.0M
- Location
- Boston, United States
- Priority score
- 50/100
- Confidence
- 70/100
Series D
Life Biosciences.
Life Biosciences pioneers cellular rejuvenation using partial epigenetic reprogramming (PER) with OSK transcription factors to reverse age-related diseases.